Moscow, Russia, January 2014. "TheraMAB" LLC. announces the beginning of multicenter Phase Ib/IIa clinical trial of multiple TAB08 i.v. administration. This is “first-in-class” anti-CD28 humanized mAb of IgG4 type for the treatment...
The Skolkovo Fund has approved a $5m grant to TheraMAB, innovation and venture news source UNOVA reports. The money will be reportedly spent on development of a medicine that can selectively modulate activity of T-lymphocytes for treating rheumatoid arthritis...